Acute Coronary Syndromes

  • Steven HollenbergEmail author
  • Stephen Heitner
Part of the Current Clinical Practice book series (CCP, volume 1)


Acute coronary syndromes (ACS) describe the spectrum of disease in patients who present with clinical symptoms compatible with acute myocardial ischemia. ACS are a family of disorders that share similar pathogenic mechanisms and represent different points along a common continuum. These syndromes are caused by recent thrombus formation on preexisting coronary artery plaque leading to impaired myocardial oxygen supply. In this sense they differ from stable angina, which is usually precipitated by increased myocardial oxygen demand (e.g. exertion, fever, tachycardia) with background coronary artery narrowing (limitation of oxygen supply).


Percutaneous Coronary Intervention Acute Coronary Syndrome Thrombolytic Therapy Cardiogenic Shock Leave Bundle Branch Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–72.PubMedGoogle Scholar
  2. 2.
    Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002;105:2000–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Croft CH, Nicod P, Corbett JR, et al. Detection of acute right ventricular infarction by right precordial electrocardiography. Am J Cardiol. 1982;50:421–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis. Significance of PR segment and PR vector changes. Circulation. 1973;48:575–80.PubMedGoogle Scholar
  5. 5.
    Goodman SG, Fu Y, Langer A, et al. The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. Am Heart J. 2006;152:277–84.PubMedCrossRefGoogle Scholar
  6. 6.
    Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation. 1999;99:1671–7.PubMedGoogle Scholar
  7. 7.
    Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation. 2008;118:2200–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;106:803–77.CrossRefGoogle Scholar
  10. 10.
    Kushner FG, Hand M, Smith Jr SC, et al. 2009 Focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–330.PubMedCrossRefGoogle Scholar
  11. 11.
    Gruppo Italiano per lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;2:397–402.Google Scholar
  12. 12.
    TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932–6.Google Scholar
  13. 13.
    GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–22.CrossRefGoogle Scholar
  14. 14.
    GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.CrossRefGoogle Scholar
  15. 15.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118–23.CrossRefGoogle Scholar
  16. 16.
    Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716–22.CrossRefGoogle Scholar
  17. 17.
    Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673–9.PubMedCrossRefGoogle Scholar
  18. 18.
    GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775–82.CrossRefGoogle Scholar
  19. 19.
    Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Anderson RD, White HD, Ohman EM, et al. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO III trial. Am Heart J. 2002;144:81–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548–54.PubMedGoogle Scholar
  26. 26.
    ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–60.Google Scholar
  27. 27.
    Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396–403.PubMedCrossRefGoogle Scholar
  28. 28.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89.PubMedCrossRefGoogle Scholar
  30. 30.
    Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. 2000;36:2028–35.PubMedCrossRefGoogle Scholar
  34. 34.
    Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903.PubMedCrossRefGoogle Scholar
  35. 35.
    Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Van’t Hof AW, Ten Berg J, Heestermans T. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537–46.PubMedCrossRefGoogle Scholar
  39. 39.
    Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–88.PubMedCrossRefGoogle Scholar
  40. 40.
    Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135–42.PubMedCrossRefGoogle Scholar
  41. 41.
    Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008;156:44–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Cohn PF, Gorlin R. Physiologic and clinical actions of nitroglycerin. Med Clin North Am. 1974;58:407–15.PubMedGoogle Scholar
  44. 44.
    Gruppo Italiano per lo Studio Della Sopravvinza Nell’Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115–22.Google Scholar
  45. 45.
    ISIS-4 (Fourth International Study of Infarct Survival) Study Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–85.CrossRefGoogle Scholar
  46. 46.
    First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66.Google Scholar
  47. 47.
    TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med. 1989;320:618–27.CrossRefGoogle Scholar
  48. 48.
    Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–32.PubMedCrossRefGoogle Scholar
  49. 49.
    MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985;6:199–226.Google Scholar
  50. 50.
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–74.CrossRefGoogle Scholar
  52. 52.
    Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.PubMedCrossRefGoogle Scholar
  53. 53.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  54. 54.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  55. 55.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.CrossRefGoogle Scholar
  56. 56.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
  58. 58.
    Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107:149–58.PubMedCrossRefGoogle Scholar
  59. 59.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRefGoogle Scholar
  60. 60.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669–77.PubMedCrossRefGoogle Scholar
  61. 61.
    Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678–84.PubMedCrossRefGoogle Scholar
  62. 62.
    Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–31.PubMedGoogle Scholar
  63. 63.
    Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-q-wave myocardial infarction. N Engl J Med. 1986;315:423–9.PubMedCrossRefGoogle Scholar
  64. 64.
    MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. J Am Med Assoc. 1988;260:1910–6.CrossRefGoogle Scholar
  65. 65.
    Lauler DP. Magnesium – coming of age. Am J Cardiol. 1989;63:1g–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Braunwald E. Unstable angina. A classification. Circulation. 1989;80:413–4.CrossRefGoogle Scholar
  67. 67.
    Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996;335:1333–41.PubMedCrossRefGoogle Scholar
  68. 68.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369–75.PubMedCrossRefGoogle Scholar
  69. 69.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.PubMedCrossRefGoogle Scholar
  70. 70.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRefGoogle Scholar
  71. 71.
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–601.PubMedGoogle Scholar
  74. 74.
    Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54.PubMedCrossRefGoogle Scholar
  75. 75.
    Investigators TIMI. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Circulation. 1994;89:1545–56.Google Scholar
  76. 76.
    Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785–92.PubMedCrossRefGoogle Scholar
  77. 77.
    FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–15.CrossRefGoogle Scholar
  78. 78.
    Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–87.PubMedCrossRefGoogle Scholar
  79. 79.
    RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet. 1993;341:573–80.CrossRefGoogle Scholar
  80. 80.
    Hirsch A, Windhausen F, Tijssen JG, Verheugt FW, Cornel JH, de Winter RJ. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet. 2007;369:827–35.PubMedCrossRefGoogle Scholar
  81. 81.
    Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165–75.PubMedCrossRefGoogle Scholar
  82. 82.
    Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705–18.PubMedCrossRefGoogle Scholar
  83. 83.
    Reardon MJ, Carr CL, Diamond A, et al. Ischemic left ventricular free wall rupture: prediction, diagnosis, and treatment. Ann Thorac Surg. 1997;64:1509–13.PubMedCrossRefGoogle Scholar
  84. 84.
    Killen DA, Piehler JM, Borkon AM, Gorton ME, Reed WA. Early repair of postinfarction ventricular septal rupture. Ann Thorac Surg. 1997;63:138–42.PubMedCrossRefGoogle Scholar
  85. 85.
    Khan SS, Gray RJ. Valvular emergencies. Cardiol Clin. 1991;9:689–709.PubMedGoogle Scholar
  86. 86.
    Bolooki H. Emergency cardiac procedures in patients in cardiogenic shock due to complications of coronary artery disease. Circulation. 1989;79:I137–48.PubMedGoogle Scholar
  87. 87.
    Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008;52:319–26.PubMedCrossRefGoogle Scholar
  88. 88.
    Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med. 1993;328:981–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Nedeljkovic ZS, Ryan TJ. Right ventricular infarction. In: Hollenberg SM, Bates ER, editors. Cardiogenic shock. Armonk, NY: Futura; 2002. p. 161–86.Google Scholar
  90. 90.
    Dell’Italia LJ, Starling MR, Blumhardt R, Lasher JC, O’Rourke RA. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction. Circulation. 1985;72:1327–35.PubMedCrossRefGoogle Scholar
  91. 91.
    Bowers TR, O’Neill WW, Grines C, Pica MC, Safian RD, Goldstein JA. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med. 1998;338:933–40.PubMedCrossRefGoogle Scholar
  92. 92.
    Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med. 1999;131:47–59.PubMedGoogle Scholar
  93. 93.
    Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009;119:1211–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. Circulation. 1995;91:873–81.PubMedGoogle Scholar
  95. 95.
    Holmes Jr DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol. 1995;26:668–74.PubMedCrossRefGoogle Scholar
  96. 96.
    De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–89.PubMedCrossRefGoogle Scholar
  97. 97.
    Hollenberg SM, Parrillo JE. Shock. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 14th ed. New York: McGraw-Hill; 1997. p. 214–22.Google Scholar
  98. 98.
    Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8:723–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007;35:2732–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883–91.PubMedCrossRefGoogle Scholar
  101. 101.
    Willerson JT, Curry GC, Watson JT, et al. Intraaortic balloon counterpulsation in patients in cardiogenic shock, medically refractory left ventricular failure and/or recurrent ventricular tachycardia. Am J Med. 1975;58:183–91.PubMedCrossRefGoogle Scholar
  102. 102.
    Bates ER, Stomel RJ, Hochman JS, Ohman EM. The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. Int J Cardiol. 1998;65 Suppl 1:S37–42.PubMedCrossRefGoogle Scholar
  103. 103.
    Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36:1123–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Becker RC. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J. 1993;125:919–29.PubMedCrossRefGoogle Scholar
  105. 105.
    Garber PJ, Mathieson AL, Ducas J, Patton JN, Geddes JS, Prewitt RM. Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol. 1995;11:30–6.PubMedGoogle Scholar
  106. 106.
    Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511–5.PubMedCrossRefGoogle Scholar
  107. 107.
    Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625–34.PubMedCrossRefGoogle Scholar
  108. 108.
    Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J. 1999;20:1030–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Cooper University HospitalCamdenUSA
  2. 2.Robert Wood Johnson Medical SchoolUniversity of Medicine and Dentistry of Section of Cardiology Cooper University HospitalCamdenUSA

Personalised recommendations